These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 12594828)

  • 1. C-kit+ FcR+ myelocytes are increased in cancer and prevent the proliferation of fully cytolytic T cells in the presence of immune serum.
    Beck C; Schreiber K; Schreiber H; Rowley DA
    Eur J Immunol; 2003 Jan; 33(1):19-28. PubMed ID: 12594828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of TGF-beta in immune-evasion of cancer.
    Beck C; Schreiber H; Rowley D
    Microsc Res Tech; 2001 Feb; 52(4):387-95. PubMed ID: 11170297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
    Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal restriction of the expansion of antigen-specific CD8+ memory T cells by transforming growth factor-{beta}.
    Cheng ML; Chen HW; Tsai JP; Lee YP; Shih YC; Chang CM; Ting CC
    J Leukoc Biol; 2006 May; 79(5):1033-42. PubMed ID: 16478921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
    Kausche S; Wehler T; Schnürer E; Lennerz V; Brenner W; Melchior S; Gröne M; Nonn M; Strand S; Meyer R; Ranieri E; Huber C; Falk CS; Herr W
    Cancer Res; 2006 Dec; 66(23):11447-54. PubMed ID: 17145892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack.
    Koehler H; Kofler D; Hombach A; Abken H
    Cancer Res; 2007 Mar; 67(5):2265-73. PubMed ID: 17332357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
    Janicki CN; Jenkinson SR; Williams NA; Morgan DJ
    Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity.
    Saha A; Chatterjee SK; Foon KA; Primus FJ; Bhattacharya-Chatterjee M
    Cancer Res; 2003 Jun; 63(11):2844-54. PubMed ID: 12782590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B7.2-Ig fusion proteins enhance IL-4-dependent differentiation of tumor-sensitized CD8+ cytotoxic T lymphocyte precursors.
    Hiraoka S; Takeuchi N; Bian Y; Nakahara H; Kogo M; Dunussi-Joannopoulos K; Wolf S; Ono S; Fujiwara H
    Int Immunol; 2005 Aug; 17(8):1071-9. PubMed ID: 16027141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells.
    Waeckerle-Men Y; Starke A; Wüthrich RP
    Nephrol Dial Transplant; 2007 Jun; 22(6):1527-36. PubMed ID: 17339272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TCR transgenic CD8+ T cells activated in the presence of TGFbeta express FoxP3 and mediate linked suppression of primary immune responses and cardiac allograft rejection.
    Kapp JA; Honjo K; Kapp LM; Xu Xy; Cozier A; Bucy RP
    Int Immunol; 2006 Nov; 18(11):1549-62. PubMed ID: 16966495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice.
    Distler E; Wölfel C; Köhler S; Nonn M; Kaus N; Schnürer E; Meyer RG; Wehler TC; Huber C; Wölfel T; Hartwig UF; Herr W
    Exp Hematol; 2008 Apr; 36(4):451-63. PubMed ID: 18261837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y; Huang H; Chen Z; Zong L; Xiang J
    J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
    VanOosten RL; Griffith TS
    Cancer Res; 2007 Dec; 67(24):11980-90. PubMed ID: 18089829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunotherapeutic efficacy of both helper T lymphocytes and cytotoxic T lymphocytes epitopes augmented dendritic cells tumor vaccine on gastric cancer].
    Li Q; Zhang Y; Chen XH; Cao WX; Gu QL; Zhu ZG; Liu BY
    Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Mar; 9(2):148-51. PubMed ID: 16555158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptotic pathways are selectively activated by granzyme A and/or granzyme B in CTL-mediated target cell lysis.
    Pardo J; Bosque A; Brehm R; Wallich R; Naval J; Müllbacher A; Anel A; Simon MM
    J Cell Biol; 2004 Nov; 167(3):457-68. PubMed ID: 15534000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro anti-tumor effect of CTL induced by HSP70-Id complex-modified dendritic cells].
    Wang ZH; Ye Q; Hu ZQ; Ye ZQ; Yu X; Shen GX
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):481-5. PubMed ID: 17147108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
    Suzuki E; Kapoor V; Cheung HK; Ling LE; DeLong PA; Kaiser LR; Albelda SM
    Clin Cancer Res; 2004 Sep; 10(17):5907-18. PubMed ID: 15355924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.